DataVXACS Applied Materials & InterfacesPaper
journal article·2021-09-29Open access

HAP-Multitag, a PET and Positive MRI Contrast Nanotracer for the Longitudinal Characterization of Vascular Calcifications in Atherosclerosis

Juan Pellico, Irene Fernández-Barahona, Jesús Ruiz-Cabello, Lucía Gutiérrez, María Muñoz-Hernando, María J. Sánchez-Guisado, Irati Aiestaran-Zelaia, Lydia Martínez-Parra, Ignacio Rodríguez, Jacob Bentzon, Fernando Herranz

ACS Applied Materials & Interfaces· Volume 13· Issue 38
Publisher pageOpen full text
Source abstract

Abstract

Vascular microcalcifications are associated with atherosclerosis plaque instability and, therefore, to increased mortality. Because of this key role, several imaging probes have been developed for their in vivo identification. Among them, [18F]FNa is the gold standard, showing a large uptake in the whole skeleton by positron emission tomography. Here, we push the field toward the combined anatomical and functional early characterization of atherosclerosis. For this, we have developed hydroxyapatite (HAP)-multitag, a bisphosphonate-functionalized 68Ga core-doped magnetic nanoparticle showing high affinity toward most common calcium salts present in microcalcifications, particularly HAP. We characterized this interaction in vitro and in vivo, showing a massive uptake in the atherosclerotic lesion identified by positron emission tomography (PET) and positive contrast magnetic resonance imaging (MRI). In addition, this accumulation was found to be dependent on the calcification progression, with a maximum uptake in the microcalcification stage. These results confirmed the ability of HAP-multitag to identify vascular calcifications by PET/(T1)MRI during the vulnerable stages of the plaque progression.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

Nanomaterials

OpenAlex topics: Parathyroid Disorders and Treatments · Cerebrovascular and Carotid Artery Diseases · Connective tissue disorders research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CIBER de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain

School of Biomedical Engineering & Imaging Sciences, King’s College London, St. Thomas’ Hospital, SE1 7EH London, U.K.

Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain

NanoMedMol Group, Instituto de Química Medica (IQM), Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain

Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia San Sebastián, Spain

IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain

Departamento de Química Analítica, Instituto de Nanociencia y Materiales de Aragón, Universidad de Zaragoza-CSIC y CIBER-BBN, 50018 Zaragoza, Spain

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain

Funding

Fundaci??n BBVA · Ministerio de Econom??a, Industria y Competitividad, Gobierno de Espa??a · Ministerio de Ciencia e Innovaci??n · Eusko Jaurlaritza · Centro Nacional de Investigaciones Cardiovasculares · Agencia Estatal de Investigaci??n

References (33)

Show source-provided references
1. 10.1016/j.jbiomech.2019.03.00510.1016/j.jbiomech.2019.03.005 ↗
2. 10.1161/JAHA.117.00735610.1161/JAHA.117.007356 ↗
3. 10.1111/1744-9987.1266210.1111/1744-9987.12662 ↗
4. 10.1161/atvbaha.120.31378510.1161/atvbaha.120.313785 ↗
5. 10.1021/acs.bioconjchem.0c0040110.1021/acs.bioconjchem.0c00401 ↗
6. 10.1039/c4ra13824d10.1039/c4ra13824d ↗
7. 10.1002/adhm.20180020210.1002/adhm.201800202 ↗
8. 10.1039/c4dt02965h10.1039/c4dt02965h ↗
9. 10.2967/jnumed.110.07793310.2967/jnumed.110.077933 ↗
10. 10.1016/j.nucmedbio.2014.11.01010.1016/j.nucmedbio.2014.11.010 ↗
11. 10.1007/s11307-015-0836-610.1007/s11307-015-0836-6 ↗
12. 10.2967/jnumed.114.13917010.2967/jnumed.114.139170 ↗
13. 10.1002/jmri.2571110.1002/jmri.25711 ↗
14. 10.1038/nm170010.1038/nm1700 ↗
15. 10.1016/j.jcmg.2016.09.02910.1016/j.jcmg.2016.09.029 ↗
16. 10.1016/j.addr.2019.01.00510.1016/j.addr.2019.01.005 ↗
17. 10.1021/ja203340u10.1021/ja203340u ↗
18. 10.1021/nl902715v10.1021/nl902715v ↗
19. 10.1021/acs.langmuir.7b0175910.1021/acs.langmuir.7b01759 ↗
20. 10.1021/acsomega.8b0300410.1021/acsomega.8b03004 ↗
21. 10.1002/cmmi.168110.1002/cmmi.1681 ↗
22. 10.1038/s41598-017-12829-y10.1038/s41598-017-12829-y ↗
23. 10.3390/pharmaceutics1203029310.3390/pharmaceutics12030293 ↗
24. 10.1021/bc500536y10.1021/bc500536y ↗
25. 10.1002/chem.20150045810.1002/chem.201500458 ↗
26. 10.1161/01.atv.14.1.13310.1161/01.atv.14.1.133 ↗
27. 10.1016/j.ejphar.2017.05.01010.1016/j.ejphar.2017.05.010 ↗
28. 10.1038/s41598-018-19628-z10.1038/s41598-018-19628-z ↗
29. 10.2967/jnumed.115.15422910.2967/jnumed.115.154229 ↗
30. 10.1038/ncomms849510.1038/ncomms8495 ↗
31. 10.1007/s10554-020-02019-910.1007/s10554-020-02019-9 ↗
32. 10.3791/5401710.3791/54017 ↗
33. 10.3389/fcvm.2018.0003610.3389/fcvm.2018.00036 ↗